Ricercatori hanno identificato la via genetica presente nelle cellule del malanoma in grado di inibire il meccanismo cellulare che identifica il danno del DNA indotta dalla chemioterapia il che risulta la maggior ragione della resistenza del melanoma alla terapia medica. Quindi colpendo questa via che comprende i geni RhoJ and Pak1, si propone un nuovo approccio
Dr Georgina Long from Westmead Hospital and the Melanoma Institute Australia and colleagues report that combining the new drugs dabrafenib and trametinib provided a clinically meaningful improvement in progression-free survival, response rate and duration of response in 162 patients with melanoma that had BRAF V600 mutations. Patients in the study received either dabrafenib 150mg twice daily;
Nella cura del melanoma metastatico si rivela promettente la terapia di associazione tra dabrafenib (un BRAF inibitore) e trametenib (MEK inibitore). Tale associazione rivela un allungamento della vita rispetto ai pazienti trattati con solo dabrafenib. I risultati sono stati presentati a ESMO 2012 Congress of the European Society for Medical Oncology a Vienna. Lo studio è in
Studies have demonstrated a higher rate of nodal metastases in melanoma of childhood, but there is controversy about the overall prognosis relative to adults. We describe a large single-institution experience with pediatric melanoma and assess prognostic characteristics Retrospective review identified 126 patients diagnosed with melanoma at <21 years of age and referred for treatment from 1986 to
Studies have demonstrated a higher rate of nodal metastases in melanoma of childhood, but there is controversy about the overall prognosis relative to adults. We describe a large single-institution experience with pediatric melanoma and assess prognostic characteristics Retrospective review identified 126 patients diagnosed with melanoma at <21 years of age and referred for treatment from 1986 to
Uno studio eseguito in Germania ha evidenziato che cavie geneticamente predisposte ad avere un melanoma a cui era somministrato Viagra con l’acqua, avevano una sopravvivenza due volte superiore alle cavie non trattate. Il farmaco agirebbe sul sistema immunitario rendendolo più efficace nel combattere il melanoma. Lo studio è stato eseguito da ricervìcatori del German Cancer
Monoclonal antibodies directed against the immune checkpoint protein cytotoxic T-lymphocyte antigen-4 (CTLA-4; CD152)—ipilimumab and tremelimumab—have been investigated in metastatic melanoma and other cancers and have shown promising results. Recently, ipilimumab was approved by the US Food and Drug Administration for the treatment of metastatic melanoma. We review the literature on managing the adverse effects and
Un articolo pubblicato nel Journal of Clinical Oncology evidenzia la gestione degli effetti collaterali della terapia con ipilimumab e tremelimumab nel melanoma metastatico: “Monoclonal antibodies directed against the immune checkpoint protein cytotoxic T-lymphocyte antigen-4 (CTLA-4; CD152)—ipilimumab and tremelimumab—have been investigated in metastatic melanoma and other cancers and have shown promising results. Recently, ipilimumab was approved
A laboratory study led by UNC medical oncologist Stergios Moschos, MD, demonstrates how a new targeted drug, Elesclomol, blocks oxidative phosphorylation, which appears to play essential role in melanoma that has not been well-understood. Elesclomol (Synta Pharmaceuticals, Lexington, MA) was previously shown to have clinical benefit only in patients with normal serum lactate dehydrogenase (LDH), a
A laboratory study led by UNC medical oncologist Stergios Moschos, MD, demonstrates how a new targeted drug, Elesclomol, blocks oxidative phosphorylation, which appears to play essential role in melanoma that has not been well-understood. Elesclomol (Synta Pharmaceuticals, Lexington, MA) was previously shown to have clinical benefit only in patients with normal serum lactate dehydrogenase (LDH), a